List of Field Safety Notices from 10 to 14 November 2025.
Similar Posts
Guidance: Paclitaxel drug-coated balloons and drug-eluting stents
Recommendations from the independent Expert Advisory Group to the MHRA on the use of paclitaxel balloon catheters and stents to treat peripheral arterial disease.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2024 to 2025
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
MHRA Safety Roundup: May 2025
Summary of the latest safety advice for medicines and medical device users
Valproate – reproductive risks
Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm.
Electronic Common Technical Document (eCTD) submissions update
Since, April 2024, the MHRA has been using Lorenz DocuBridge for eCTD management in product license submissions. This change is part of the modernisation of the MHRA’s Legacy Systems and is one of the initial tools launched in the RegulatoryConnect programme.
MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection
As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review.